Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extraesophageal reflux symptoms

Medicine (United States)

Volumn 95, Issue 32, 2016, Pages

  Kim, Jin Joo ^a,b   Kim, Nayoung ^a,c   Choi, Yoon Jin ^a,c   Kim, Joo Sung ^a   Jung, Hyun Chae ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

gastroesophageal reflux disease; glial cell derived neurotrophic factor; nerve growth factor; proteinase activated receptor 2; transient receptor potential vanilloid receptor 1

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 8; MESSENGER RNA; NERVE GROWTH FACTOR; PROTEINASE ACTIVATED RECEPTOR 2; PROTON PUMP INHIBITOR; VANILLOID RECEPTOR 1; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; EPIGASTRIC DISCOMFORT; ESOPHAGOSCOPY; FEMALE; HOARSENESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON EROSIVE REFLUX DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REFLUX ESOPHAGITIS; STATISTICAL SIGNIFICANCE; THORAX PAIN; UPREGULATION; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; DISEASE COURSE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION REGULATION; GENETICS; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHEST PAIN; COUGH; DISEASE PROGRESSION; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, PAR-2; REFERENCE VALUES; RISK ASSESSMENT; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TRPV CATION CHANNELS; UP-REGULATION;

EID: 84983430701     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004387     Document Type: Article

References (36)

1. Boeckxstaens G, El-Serag HB, Smout AJ, et al. Symptomatic reflux disease: the present, the past and the future. Gut 2014;63:1185-93
2. Altomare A, Guarino MP, Cocca S, et al. Gastroesophageal reflux disease: Update on inflammation and symptom perception. World J Gastroenterol 2013;21:6523-8
3. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771-8
4. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002;50:451-9
5. Fiocca R, Mastracci L, Engström C, et al. Longterm outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am J Gastroenterol 2010;105:1015-23
6. Mönkemüller K, Wex T, Kuester D, et al. Interleukin-1beta and interleukin-8 expression correlate with the histomorphological changes in esophageal mucosa of patients with erosive and non-erosive reflux disease. Digestion 2009;79:186-95
7. Rafiee P, Nelson VM, Manley S, et al. Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2009;296:388-98
8. Ma J, Altomare A, Guarino M, et al. HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2012;303:635-45
9. Cheng HH, Chang CS, Wang HJ, et al. Interleukin-1beta and-10 polymorphisms influence erosive reflux esophagitis and gastritis in Taiwanese patients. J Gastroenterol Hepatol 2010;25:1443-51
10. Queiroz DM, Guerra JB, Rocha GA, et al. IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Gastroenterology 2004;127:73-9
11. Yoshida N, Katada K, Handa O, et al. Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med 2007;19:335-40
12. Huang SC. Protease-activated receptor-1 (PAR1) and PAR2 but not PAR4 mediate relaxations in lower esophageal sphincter. Regul Pept 2007;142:37-43
13. Chen K, Zhang ZF, LiaoMF, et al. Blocking PAR2 attenuates oxaliplatininduced neuropathic pain via TRPV1 and releases of substance P and CGRP in superficial dorsal horn of spinal cord. JNeurol Sci 2015;15:62-7
14. Ma J, Altomare A, Guarino M, et al. HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2012;303:G635-45
15. Yoshida N, Kuroda M, Suzuki T, et al. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig Dis Sci 2013;58:2237-43
16. Choi YJ, Kim N, Kim J, et al. Upregulation of vanilloid receptor-1 in functional dyspepsia with or without Helicobacter pylori infection. Medicine (Baltimore) 2016;95:e3410
17. Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxelinduced neuropathic pain. Neuroscience 2011;193:440-51
18. Huang ZJ, Li HC, Cowan AA, et al. Chronic compression or acute dissociation of dorsal root ganglion induces cAMP-dependent neuronal hyperexcitability through activation of PAR2. Pain 2012;153:1426-37
19. Guarino MP, Cheng L, Ma J, et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 2010;22:746-51
20. Shan J, Oshima T, Chen X, et al. Trypsin impaired epithelial barrier function and induced IL-8 secretion through basolateral PAR-2: a lesson from a stratified squamous epithelial model. Am J Physiol Gastrointest Liver Physiol 2012;15:G1105-12
21. Isomoto H, Nishi Y, Kanazawa Y, et al. Immune and Inflammatory Responses in GERD and Lansoprazole. J Clin Biochem Nutr 2007;41: 84-91
22. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111:85-92
23. Jo SY, Kim N, Lim JH, et al. Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. J Neurogastroenterol Motil 2013;19:61-9
24. Kim JY, Kim N, Seo PJ, et al. Association of sleep dysfunction and emotional status with gastroesophageal reflux disease in Korea. J Neurolgastroenterol Motil 2013;19:344-54
25. Kim SE, KimN,Oh S, et al. Predictive factors of response to proton pump inhibitors in Korean patients with gastroesophageal reflux disease. J Neurolgastroenterol Motil 2015;21:69-77
26. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 2011;17:14-27
27. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 2005;22:79-94
28. Lee ES, Kim N, Lee SH, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive esophagitis and non-erosive reflux disease. Aliment Pharmacol Ther 2009;30: 154-64
29. MohdH, Qua CS,Wong CH, et al. Non-cardiac chest pain: prevalence of reflux disease and response to acid suppression in an Asian population. J Gastroenterol Hepatol 2009;24:288-93
30. Chunlertrith K, Boonsawat W, Zaeoue U. Prevalence of gastroesophageal reflux symptoms in asthma patients at Srinagarind Hospital. J Med Assoc Thai 2005;88:668-71
31. Qua CS,Wong CH, Gopala K, et al. Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy. Aliment Pharmacol Ther 2007;25:287-95
32. Heading RC, Monnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011;11:52
33. Goh KL, Choi MG, Hsu WP, et al. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific survey. J Gastroenterol Hepatol 2014;29: 1969-75
34. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005;100:537-42
35. Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with protonpump inhibitors as a test for gastroesophageal reflux disease: a metaanalysis of diagnostic test characteristics. Ann Intern Med 2004;140: 518-27
36. Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010;59:714-21